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We present the case of a 33-year-old chronic myeloid leu-
kemia (CML) female patient, in whom the occurrence of 
nephrotic syndrome, during the treatment with tyrosine 
kinase activity inhibitors (TKIs), was potentially influenced 
by transient phenoconversion. Seven years after the CML 
diagnosis in 2004 and complete response, the patient ex-
perienced pain in the mandible and extremities. After this, 
imatinib was replaced by nilotinib, but generalized macu-
lopapular rash was presented and successfully treated with 
antihistamines. The therapy was then discontinued due to 
planned pregnancy, and the patient experienced a relapse 
of CML with BCR-ABL/ABL1 transcripts of 18.9%. Dasatinib 
was introduced, and CML was in remission. Two years later, 
urine protein levels (6.19 g/L) and erythrocyte sedimenta-
tion rate were elevated (ESR = 90 mm/3.6 ks). The patient 
was diagnosed with nephrotic syndrome. With dasatinib 
dose reduction, urine protein level returned to the refer-
ence range. In order to determine the best genotype-guid-
ed therapy, the patient underwent pharmacogenomic 
testing, showing a homozygous CYP3A4 genotype *1/*1, 
associated with extensive metabolizer (EM) enzyme phe-
notype, typical for normal rates of drug metabolism for TKIs. 
However, this was inconsistent with nephrotic syndrome 
occurrence. A possible explanation would be CYP3A4 EM 
genotype coding a poor metabolizer enzyme phenotype, 
leading to the drug accumulation in the patient’s blood. 
This transient phenoconversion can be explained by in-
flammation with elevated ESR during nephrotic syndrome. 
This case shows that a broader approach that recognizes 
genetic, clinical, and epigenomic factors is required for a 
quality decision on the personalized therapy regimen.
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We present the case of a 33-year-old chronic myeloid leu-
kemia (CML) female patient, in whom nephrotic syndrome, 
during the treatment with tyrosine kinase activity inhibi-
tors (TKIs), was potentially influenced by transient pheno-
conversion. Given the variable response to TKIs in patients 
with CML and constant dilemmas related to adverse drug 
reactions (ADRs) to TKIs, this case highlights a huge poten-
tial of pharmacogenomics in making optimal therapeutic 
decisions, even in the case of poor drug tolerability that 
otherwise may prompt physicians to stop the therapeutic 
regimen and jeopardize the treatment outcome. In addi-
tion, in this case report, we discuss the adverse impact of 
phenoconversion on the success of genotype-based pre-
scribing decisions.
CAse PResentAtIon
The patient was diagnosed with CML in June 2004, after 
which she immediately started TKI therapy and had com-
plete hematological, cytogenetic, and deep molecular re-
sponse to therapy, but at a cost of persistent adverse drug 
reactions.
Seven years after the CML diagnosis and complete re-
sponse, she experienced pain in the mandible and ex-
tremities. Imatinib was replaced by nilotinib, but general-
ized maculopapular rash was presented and successfully 
treated with antihistamines. The therapy was then dis-
continued due to planned pregnancy, and the patient 
experienced a relapse of CML with BCR-ABL/ABL1 tran-
scripts of 18.9%. Dasatinib was introduced, and CML was 
in remission. Two years later, urine protein levels (6.19 
g/L) and erythrocyte sedimentation rate were elevated 
(ESR = 90 mm/3.6 ks). The patient was diagnosed with 
nephrotic syndrome, and clinical investigation was con-
ducted in order to determine its etiology. At that point, 
the patient did not have any signs of infection and did 
not take any nonsteroidal anti-inflammatory drugs or any 
other concomitant medication. She was examined by a 
nephrologist, who did not find indication for renal biopsy 
because drug-induced proteinuria was presumed. With 
dasatinib dose reduction, urine protein levels were re-
turned to the reference range. In order to determine the 
best genotype-guided therapy, the patient underwent 
pharmacogenomic testing. The analysis showed that she 
had a homozygous CYP3A4 genotype *1/*1, associated 
with extensive metabolizer (EM) enzyme phenotype, typ-
ical for normal rates of drug metabolism for TKIs. How-
ever, this was inconsistent with nephrotic syndrome oc-
currence.
A possible explanation would be that CYP3A4 EM geno-
type coded a poor metabolizer (PM) enzyme phenotype, 
which led to the drug accumulation in the patient’s blood. 
This transient phenoconversion can be explained by in-
flammation with elevated ESR during nephrotic syndrome. 
The complete list of TKIs in the patient’s therapy, as well as 
all the adverse events associated with their usage, is shown 
in Table 1.
The patient was referred to the St. Catherine Hospital in 
September 2018 by her attending hematologist for phar-
macogenomic testing, due to the broad spectrum of what 
were thought to be ADRs, and for determination of the 
best genotype-guided therapy. We tested the patient for 
polymorphisms in 25 known drug metabolizing enzymes 
and receptor coding genes (Table 2), as well as prothrom-
botic factors: factor II, V and methylenetetrahydrofolate re-
ductase (MTHFR), using RightMed® panel (OneOme, Min-
neapolis, MN, USA). TaqMan real-time polymerase chain 
reaction (PCR) next-generation sequencing was performed 
to determine single nucleotide polymorphisms. The anal-
ysis showed that the patient had a homozygous CYP3A4 
genotype *1/*1, associated with EM enzyme phenotype, 
typical for normal rates of drug metabolism. The patient 
and her attending hematologist were informed that the 
described ADRs were not a product of gene-drug inter-
actions and advised that she should be guided as before, 
but with an emphasis on therapeutic drug monitoring for 
adverse events induced by either drug-drug interactions 
or by inflammation, to prevent future complications of TKI 
therapy. After the consultation with the patient’s hema-
tologist, the patient continued bosutinib 200 mg per day 
with complete molecular and hematologic response with-
out any debilitating adverse events.
DIsCussIon
The influence of the activity of CYP3A4 enzyme, the main 
enzyme metabolizing TKIs, on the pharmacokinetic profile 
of TKIs was previously reported (1). Therefore, we decided 
to test the patient’s genotype to determine her exact en-
zymatic activity. However, it is worth mentioning that re-
cent studies presumed a link between ABCB1 expression 
and TKI metabolism in vitro, but the enzyme analysis was 
not included in the panel (2). The analysis showed that the 
patient had a homozygous CYP3A4 genotype *1/*1, as-
sociated with EM enzyme phenotype (3). The result was 
inconsistent with the observed adverse events, which 
could be explained by CYP3A4 genotype coding a PM 
enzyme phenotype, leading to the drug accumula-
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netic and molecular response
June 2011 intensifying pain in the extremities and the 
mandible
NSAIDs did not reduce pain
July 2011 therapy 
cessation
pain withdrew 2 weeks after discontinua-
tion of the drug
Tasigna 
(nilotinib)
January 2012 800 mg therapy 
introduction
generalized maculopapular rash after a few 
days; successfully treated by antihistamines complete hematologic, cytoge-
netic and molecular responseFebruary 2012 therapy 
cessation
February 2012 400 mg therapy 
introduction
complete hematologic, cytoge-
netic and molecular response
dose reduction was done by the patient 
herself
March 2012 generalized maculopapular rash successfully 
treated by antihistamines
October 2012 therapy 
cessation
generalized maculopapular rash successfully 
treated by antihistamines
October 2012 200 mg therapy 
introduction
generalized maculopapular rash treated by 
antihistamines complete hematologic, cytoge-
netic and molecular responseMay 2014 therapy 
cessation
the therapy was discontinued due to preg-
nancy planning
November 2014 800 mg therapy 
introduction
generalized maculopapular rash and swelling 
of thighs unsuccessfully treated by antihista-
mines and corticosteroids BCR-ABL/ABL1: 18.9%
indicating a relapse of CMLDecember 2014 therapy
cessation
the adverse events did not respond to the 
therapy, therefore it was decided to discon-
tinue the therapy
Sprycel December 2014 100 mg therapy 
introduction
BCR-ABL/ABL1: 0.0058% indicat-
ing remission of CML
(dasatinib) April 2016 therapy  
cessation
dry skin, periorbital and peripheral edema the adverse events first happened over a 
year after therapy introduction
April 2016 80 mg therapy 
introduction
dry skin, periorbital and peripheral edema,
nausea and itching
therapy remained the same due to the 
patient’s ability to cope with adverse events
November 2016
February 2017 therapy  
cessation
worsening of adverse effects, nephrotic-type 
proteinuria and elevated ESR
urine protein levels (UPL): 6.19 
g/L†
ESR: 90 mm/3.6 ks‡
February 2017 40 mg therapy 
introduction
improved general well-being of the patient
March 2017 UPL: 1 g/L
July 2017 UPL: 1.12 g/L
October 2017 therapy  
cessation
ESR: 24 mm/3.6 ks 
Complete hematologic, cytoge-
netic and molecular remission
the therapy was discontinued due to preg-
nancy planning
Bosulif February 2018 500 mg therapy 
introduction
mandible pain and diarrhea following therapy 
introduction
increase in BCR-ABL/ABL1
the therapy was introduced due to CML 
remission
(bosutinib) May 2018 therapy 
 cessation




the diarrhea had stopped after lowering the 
drug dose and remission was achieved
August 2018 therapy 
cessation
August 2018 300 mg therapy 
introduction
confirmed major molecular response
*esR – erythrocyte sedimentation rate; CML – chronic myeloid leukemia; nsAID – nonsteroidal anti-inflammatory drugs.
†reference range <0.2 g/L
‡reference range = 4-24 mm/3.6 ks.
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tion in the patient’s blood. Nephrotic syndrome did not 
appear immediately or soon after the drug administration, 
which would indicate a typical adverse drug reaction, but 
after a period of two years. To find an explanation for the 
case, we reviewed the literature on individualized pharma-
cotherapy led by genotypization.
Previous research on genotype-based individual pharma-
cotherapy demonstrated a series of mismatches between 
an enzyme’s genotype and predicted phenotype. This is 
most commonly attributed to enzyme inhibition caused 
by drug-drug interactions or a certain diet (4,5). A differ-
ent approach to this problem would be to hypothesize 
that the elevation of proinflammatory cytokines (IL-1, IL-6, 
TNF-a), observed in conditions such as infections, diabetes, 
renal failure, or rheumatoid arthritis is capable of down-
regulating the enzyme expression by mechanisms of intra-
cellular signalization, as shown in in vitro and in vivo stud-
ies, alongside scarce clinical evidence (6,7). The described 
phenomenon is defined as phenoconversion, ie, conver-
sion of genotypic EMs or intermediate metabolizers into 
phenotypic PMs of drugs, thereby modifying their clinical 
response to that of genotypic PMs (5).
Therefore, we hypothesize that the observed spectrum of 
adverse events, including nephrotic syndrome as the most 
prominent one, during dasatinib therapy in our patient 
was influenced by transient phenoconversion of CYP3A4 
enzyme. One of the underlying mechanisms of this event 
is probably inflammation, as the adverse effect occurred in 
tandem with elevation of erythrocyte sedimentation rate 
90 mm/3.6 ks, observed in the laboratory findings. The in-
flammation could have down-regulated cytochrome P450 
enzymes, leading to dasatinib accumulation, which caused 
the adverse events.
Dasatinib has complex metabolism with five primary 
phase I metabolites, three of which are catalyzed by CY-
P3A4. The drug is a mechanism-based inactivator of CY-
P3A4 and it causes nicotinamide adenine dinucleotide 
phosphate (NADPH) and time-dependent CYP3A4 inacti-
vation. This mechanism is unique to dasatinib compared 
to other TKIs. Previous results have implied that dasatinib is 
a mechanism-based inhibitor and has more serious drug-
drug interactions than a typical competitive inhibitor (8). 
Dasatinib is unusually potent because the inactivation is 
cumulative and the enzymatic activity can only be restored 
after de novo protein synthesis. Li et al (8) have shown that 
hepatic accumulation of dasatinib or high intestinal and 
hepatic exposure during absorption may lead to higher 
than expected rates of CYP3A4 inactivation.
Moreover, it is important to underline that dasatinib could 
injure podocyte and endothelial cells through the inhi-
bition of vascular endothelial growth factor, which may 
cause proteinuria and renal thrombotic microangiopathy 
(9). A considerable number of patients developed pro-
teinuria after having been treated with dasatinib (10-14). 
Alahmari et al (10) assessed the incidence rate of TKI-as-
sociated proteinuria according to the TKI subtype in 256 
CML patients. Median follow-up duration was 31 months 
for 35 months for dasatinib (1-105 months). The incidence 
rate of proteinuria in dasatinib treated group was 29/1000 
person-year, while it was 0 in imatinib, nilotinib, bosutinib, 
and ponatinib-treated groups after having excluded sec-
ondary causes of proteinuria. Not all patients underwent 
kidney biopsy (10). In our study, nephrotic syndrome abat-
ed when dasatinib dose was decreased to 40 mg per day. 
This strengthens our hypothesis that the drug had initially 
accumulated in the patient’s blood in doses higher than 
needed, and lower daily doses were sufficient to achieve 
and retain complete therapeutic response with fewer 
ADRs. This case gave us an insight into the complexity of 
the mechanics that determine the phenotype of drug me-
tabolizing enzymes other than genotype.
The case stands to remind all those included in the 
pharmacogenomics-guided therapy process that 
tABLe 2. the list of genes responsible for the synthesis of enzymes involved in drug metabolism
Genes responsible for the synthesis of enzymes involved in the first 
phase of drug metabolism – cytochrome P450 enzymes
CPY1A2, CYP2B6, CYP2C9, CYP2C19, CYP2C Cluster, 
CYP2D6, CYP3A4, CYP3A5, CYP4F2
Genes responsible for the synthesis of enzymes involved in the second 
phase of drug metabolism
TPMT, UGT1A1
Genes responsible for the synthesis of other enzymes that are important  
for drug metabolism
DPYD, VKORC1, NUDT15
Genes responsible for the synthesis of drug transporters SLC6A4, SLCO1B1
Genes responsible for the synthesis of drug receptors HTR2A, HTR2C, DRD2, OPRM1, GRIK4, COMT
Genes responsible for the synthesis of other proteins important for drug function IFNL4, HLA-A, HLA-B
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genotype assessment of patient’s drug response is insuf-
ficient to provide complete and safe care alone. A broader 
approach that recognizes genetic, clinical, and epigenom-
ic (environmental) factors is required to make a safe and 
evidence-based decision on the personalized therapy regi-
men, alongside further development of existing guidelines 
established by Clinical Pharmacogenetics Implementation 
Consortium (https://cpicpgx.org/) and any other to come. 
Further prospective clinical studies are required to expand 
our knowledge on the implication of drug metabolizing 
enzyme genotyping on therapeutic effectiveness and pa-
tient outcome.
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